Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Dynacil; Eliten; Fosenopril sodium; Fosinil; Fosipres; Fozitec; Monopril; NewAce; SQ 27519; SQ 28555; Staril; Tensogard; Vasopril

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Boehringer Ingelheim; Bristol-Myers Squibb; Mead Johnson; Menarini
  • Class Antihypertensives; Heart failure therapies; Imino acids; Organophosphorus compounds
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Discontinued Myocardial infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Feb 2013 Cefprozil sublicensed to Swedish Orphan Biovitrum in Austria, Belgium, Ireland, United Kingdom, France, Italy Germany, Spain, Finland, Sweden, Denmark, Norway, Liechtenstein, Netherlands, Portugal, and Luxembourg
  • 31 Dec 2012 Cefprozil licensed to PharmaSwiss in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top